RPL3 and colorectal carcinoma: Some RPs are associatedwith acquired MDR.8 We have previouslydemonstrated that uL3 downregulation positivelycorrelates with MDR in p53-deleted CRC cells, and uL3 status is essentialfor cell response to anticancer drugs such as 5-FU, oxaliplatin (OHP),actinomycin D (Act D), and cisplatin.16−19 The increased resistance to 5-FUexhibited upon uL3 silencing is associated with increased cell migrationand proliferation, apoptosis inhibition, autophagy enhancement, andalteration of the epithelial–mesenchymal transition (EMT) program.20−22